PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
- PMID: 27896521
- DOI: 10.1007/s10555-016-9637-x
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment
Abstract
Anti-cancer cancer-targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Mutations in the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway are freqcuently found in breast cancers and associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK/mTOR are currently in clinical trials, mainly in combination with endocrine therapy and anti-HER2 therapy. These drugs are the focus of this review.
Keywords: AKT; Breast cancer; PI3K; mTOR.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
